Precise and Accurate CHN Data from Low Weight Samples
A new report from Exeter Analytical demonstrates how the Model 440 CHN Analyser provides precise and accurate determination of percentage carbon, hydrogen and nitrogen on samples as small as 0.3 mg.
Using Atropine (8-Methyl-8-azabicyclo[3.2.1]oct-3-yl) 3-hydroxy-2-phenylpropanoate) as the test compound the Model 440 produced data from 0.3 mg samples which only varied within +/- 0.12% of the theoretical CHN values. In environments such as pharmaceutical research and synthetic chemistry laboratories, where the weight of new compounds for analytical purposes is often limited, the ability to reliably generate reliable CHN data on sub 0.5 milligram samples is highly valuable.
The Exeter Analytical Model 440 is a static combustion CHN Elemental Analyser, with a unique horizontal furnace design, which enables easy removal of sample residue between each analysis. Because the Model 440 is able to effectively eliminate troublesome residue build-up, its gas flow characteristics are superior to other CHN Analysers leading to longer-term calibration stability, as well as enhanced accuracy and precision for measured sample data.
Because the Model 440 provides complete control over combustion parameters it is able to reproducibly achieve 100% combustion with the widest range of sample types. Through incorporation of extensive automation in the Model 440 and intuitive software – the percentage Carbon (C), Hydrogen (H) and Nitrogen (N) in samples can be determined in as little as 5 minutes.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...